CPIX

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Wall Street analysts forecast CPIX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CPIX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cumberland Pharmaceuticals Inc revenue for the last quarter amounts to 8.29M USD, decreased -8.73 % YoY.

Cumberland Pharmaceuticals Inc. EPS for the last quarter amounts to -0.13 USD, increased 18.18 % YoY.

Cumberland Pharmaceuticals Inc (CPIX) has 91 emplpoyees as of January 11 2026.

Today CPIX has the market capitalization of 74.04M USD.